Recombinant Protein Inducing Immune Tolerance for Multiple Sclerosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple sclerosis, such as disease-modifying therapy drugs, only reduce recurrence and delay progression but are ineffective for severe cases and have significant side effects, necessitating a safer and more effective approach.
Innovation Solution
A recombinant protein comprising HSP65 and 6-segment tandem repeat antigen epitope polypeptide MOG35-55, connected through a flexible joint, is developed to induce immune tolerance and used in vaccines or drugs administered intranasally to prevent multiple sclerosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If disease modifying therapy drugs are used to treat multiple sclerosis, then the recurrence rate is reduced and disease progression is delayed, but the drugs are ineffective in severe cases and cause strong side effects
Solution Approach 1:
The patent uses the autoantigen MOG35-55, which normally triggers harmful autoimmune responses, and converts this harm into benefit by immunizing with the autoantigen to induce immune tolerance. This approach transforms the harmful autoimmune reaction into a protective tolerance mechanism, eliminating the need for external DMT drugs and their associated side effects.
Solution Approach 2:
Instead of suppressing the immune response to MOG35-55 (the conventional approach), the patent inverts the strategy by actively inducing immune tolerance to the autoantigen. This inversion of the immune response strategy leads to protective effects without the harmful side effects of conventional DMT drugs.
2Reliability
If conventional DMT drugs are used, then recurrence rate is reduced, but the treatment does not cure the disease and severe cases remain ineffective
Solution Approach 1:
The patent applies preliminary action by immunizing with the autoantigen MOG35-55 before the disease progresses severely. This preventive immunization induces immune tolerance that can stop disease progression and achieve cure, rather than merely treating symptoms or reducing recurrence after disease establishment.
3Object-affected harmful factors
If autoantigen immunization is used to induce immune tolerance, then safe and effective treatment is achieved, but the immune response must be precisely controlled
Solution Approach 1:
The patent applies local quality by using a specific peptide sequence (MOG35-55) from the autoantigen rather than the entire protein. This localized peptide approach allows precise control of the immune response to specific epitopes, simplifying the complexity of inducing targeted immune tolerance without affecting other autoantigen regions.
Data Source
AI summary
The present invention discloses a recombinant protein capable of resisting multiple sclerosis and a preparation method and application thereof, and belongs to the technical field of biopharmacy. The recombinant protein of the present invention comprises Mycobacterium tuberculosis heat shock protein 65 and 6-segment tandem repeat myelin oligodendroglia glycoprotein antigen epitope polypeptides with multiple sclerosis autoimmune antigen characteristics at the 33rd-55th sites. The recombinant protein capable of resisting multiple sclerosis is used for preparing multiple sclerosis vaccines and/or preparing multiple sclerosis drugs. The present invention can play a role in preventing multiple sclerosis and can avoid side effects caused by most of disease modifying therapy (DMT) drugs.